Name:
Victoria Trial Favorable to Patients
Description:
Victoria Trial Favorable to Patients
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/6ce43005-9c4e-4e5e-b0a4-43106320a977/thumbnails/6ce43005-9c4e-4e5e-b0a4-43106320a977.jpeg?sv=2019-02-02&sr=c&sig=FlRJLMgKrmaNPucTV740QhA7TqnFvzkx5wFzEDV0x1o%3D&st=2025-05-09T09%3A53%3A37Z&se=2025-05-09T13%3A58%3A37Z&sp=r
Duration:
T00H03M27S
Embed URL:
https://stream.cadmore.media/player/6ce43005-9c4e-4e5e-b0a4-43106320a977
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/6ce43005-9c4e-4e5e-b0a4-43106320a977/18777427.mp3?sv=2019-02-02&sr=c&sig=fWyX8uvAG7vnsgBclKXoY9G8kcflwRKTywRc2sACg08%3D&st=2025-05-09T09%3A53%3A37Z&se=2025-05-09T11%3A58%3A37Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through accesscardiology.com. >> We all know that heart failure is a very bad diagnosis. And so we're -- we continue to look for newer pharmacological interventions only because of the issue related to the mortality and hospital readmissions. [ Music ] >> Hi, Dr. Bernie here and welcome to Practice Impact Extra.
Heart failure, we all know it a severe syndrome affecting 7 million Americans. It's associated with a very high rate of mortality and hospital readmissions. Newer pharmacological interventions have had a stable impact, yet many patients still have a poor quality of life and a worsening prognosis. Research has continued and will continue to look for newer pharmacological treatments to improve outcomes. So I'd like now to present the results of the VICTORIA Trial.
This trial was presented at ACC in March 2020. This was a global study in patients -- in actually severe heart failure patients with a significantly reduced ejection fraction. Vericiguat is a drug being assessed in this trial. Vericiguat acts by stimulating the production of cyclic guanosine monophosphate, which may help improve myocardial and vascular function. The trial was randomized, it was double-blinded, and enrolled very ill patients with congestive heart failure who had a recent decompensation of their heart failure.
2,600 patients were randomized to Vericiguat group and 2,600 to the placebo group. The overall mean ejection fraction was 29% and BNP levels were greater than 300. The primary endpoint was cardiovascular death or hospitalization for heart failure. So what were the outcomes at 12 months? It was noted that there was a significant decrease in the primary outcome of cardiovascular death and hospitalization.
It was 36% versus 38%. A really small absolute reduction and actually, it was driven primarily by a decrease in hospitalizations in patients who were less than 75 years of age. Cardiovascular death and all-cause mortality and serious adverse effects were similar in the two groups, and I think that's important. So what's the take-home message here? Well, Vericiguat is a new drug and hopefully, it will receive FDA approval and then could be added to the armamentarium for the treatment of very ill congestive heart failure patients.
So I urge you to stay tuned. Again, thanks for joining me, and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.
